Cagrilintide: The Long-Acting Amylin Analog Behind CagriSema

For informational purposes only. This article does not constitute medical advice. Consult a qualified healthcare provider for any health-related decisions.

What Is Cagrilintide?

Cagrilintide is an investigational long-acting analog of human amylin under development by Novo Nordisk. Amylin is a 37-amino-acid peptide hormone co-secreted with insulin from pancreatic beta cells that plays important roles in postprandial glucose regulation and satiety signaling. While the short-acting amylin analog pramlintide (Symlin) has been available since 2005, its practical utility has been limited by its short half-life and requirement for multiple daily injections. Cagrilintide was engineered to overcome these pharmacokinetic limitations, enabling once-weekly subcutaneous dosing that could be conveniently combined with other weekly injectable therapies.

The most significant aspect of cagrilintide's development is its combination with semaglutide in a single injection known as CagriSema. This combination aims to harness the complementary satiety and metabolic pathways of amylin and GLP-1 receptor agonism to achieve greater weight loss and metabolic improvement than either agent alone.

Mechanism of Action

Cagrilintide activates the amylin receptor complex (calcitonin receptor with receptor activity-modifying proteins, or RAMPs) to produce the physiological effects of amylin:

• Gastric emptying delay: Slows nutrient transit from the stomach, reducing postprandial glucose spikes and prolonging satiety.
• Postprandial glucagon suppression: Reduces inappropriate glucagon secretion after meals, limiting hepatic glucose output.
• Central satiety signaling: Activates amylin receptors in the area postrema and brainstem to promote fullness and reduce food intake through pathways distinct from GLP-1 signaling.

The combination with semaglutide in CagriSema is based on the rationale that amylin and GLP-1 activate different receptor systems in different brain regions to reduce appetite. GLP-1 acts primarily through hypothalamic circuits (arcuate nucleus, paraventricular nucleus), while amylin acts primarily through hindbrain circuits (area postrema, nucleus of the solitary tract). Engaging both pathways simultaneously may produce a more comprehensive suppression of appetite than either pathway alone.

Research Landscape

Cagrilintide Monotherapy

A Phase 2 study of cagrilintide monotherapy demonstrated dose-dependent weight loss in adults with overweight or obesity without diabetes. At the highest tested dose (4.5 mg weekly), cagrilintide produced approximately 10.8% weight loss at 26 weeks versus 3.0% with placebo. While meaningful, this was less than the weight loss observed with semaglutide 2.4 mg in the STEP trials, confirming that cagrilintide's greatest potential lies in combination rather than monotherapy.

CagriSema (Cagrilintide + Semaglutide)

The Phase 2 trial of CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg in a single weekly injection) demonstrated approximately 15.6% weight loss at 32 weeks in adults with overweight or obesity. Importantly, this exceeded the weight loss observed with either component alone at the same timepoints, providing clinical evidence for the additive benefit of dual amylin/GLP-1 receptor agonism.

Phase 3 trials of CagriSema are ongoing, with results anticipated to determine whether the combination provides clinically meaningful advantages over semaglutide alone in larger populations and over longer durations.

Key Studies

The most critical data for cagrilintide will come from the Phase 3 CagriSema trials. If the combination demonstrates meaningfully greater weight loss than semaglutide 2.4 mg alone with acceptable tolerability, it would validate the multi-hormonal approach to obesity treatment and potentially position CagriSema as Novo Nordisk's next-generation obesity therapy to compete with Eli Lilly's tirzepatide and retatrutide.

Safety Profile

The safety profile of cagrilintide in clinical trials to date has been broadly consistent with amylin receptor agonism. Gastrointestinal adverse events (nausea, vomiting, diarrhea) are the most commonly reported side effects and appear to be additive when combined with semaglutide in CagriSema, though generally manageable with dose titration. Injection site reactions have been reported at low rates. No unexpected safety signals have emerged in Phase 2 data, though Phase 3 trials with larger populations will provide more definitive safety assessments.

Comparison to Related Compounds

Compared to pramlintide, cagrilintide represents a generational advance in amylin analog pharmacology, offering weekly rather than pre-meal dosing. Compared to GLP-1 agonists alone, cagrilintide adds a complementary satiety pathway. The combination product CagriSema competes in the same therapeutic space as tirzepatide (dual GIP/GLP-1 agonist) and the investigational retatrutide (triple agonist), but through a fundamentally different multi-hormonal strategy. For a broader overview of the GLP-1 landscape, see the Complete Guide to GLP-1 Receptor Agonists.

Current Status

Cagrilintide is in Phase 3 clinical development, both as monotherapy and as part of the CagriSema combination. It is not approved by any regulatory authority and is available only through clinical trials. CagriSema represents one of the most anticipated products in Novo Nordisk's obesity pipeline and could become a key competitor to Eli Lilly's dual and triple agonist programs if Phase 3 results confirm the Phase 2 signal of enhanced efficacy through dual amylin/GLP-1 agonism.